期刊名称：JOURNAL OF HEPATOCELLULAR CARCINOMA
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Aims and Scope
The Journal of Hepatocellular Carcinoma is an international, peer-reviewed, open access journal.
The journal provides the international community with a platform for the dissemination and study of clinical, translational, and basic research findings in this rapidly developing field. Primary liver tumors, primarily hepatocellular carcinoma (HCC), are the third leading cause of cancer death worldwide, with around 750,000 new cases annually, and around 700,000 deaths. While 80% occurs in the developing world, the incidence is beginning to decline due to hepatitis B vaccination and developments in food hygiene; conversely, there is an increasing incidence in the developed world, partly due to metabolic syndrome, obesity and diabetes.
The journal welcomes original research manuscripts, reviews, clinical trial reports, expert opinions and commentaries relating to all aspects of HCC, spanning from basic laboratory research through to clinical and translational research.
Meta-analyses will no longer be considered for publication.
Specific topics covered by the journal include:
- cell signalling pathways
- molecular tumor classification and prognostication
- new drugs and other therapies
- new radiology approaches
- epidemiology, surveillance, and prevention
- psychosocial aspects and quality of life issues
The journal will consider case reports only if they make a valuable and original contribution to the literature. Study protocols are not suitable unless at least pilot or baseline data are provided.
When considering submission of a paper utilizing publicly available data, authors should ensure that such studies add significantly to the body of knowledge and that they are validated using the authors’ own data through replication in an original sample.
Indexed online:
- PubMed and PubMed Central (J Hepatocell Carcinoma)
- Science Citation Index Expanded (also known as SciSearch®)
- Journal Citation Reports/Science Edition
- Current Contents®/Life Sciences
- Embase, from 2018 (Correct as at September 10, 2018)
- Directory of Open Access Journals (DOAJ)
- OAIster: The Open Access Initiative
Instructions to Authors
Manuscript preparation
- While the editors fully understand the extra challenges posed to authors whose native language is not English, we must ask that all manuscripts be reviewed and edited by a native speaker of English with expertise in that area prior to submission
- Double-spacing
- 3-cm margins
- Page numbers
- Line numbers
- Clear concise language
- American spelling (all components of a manuscript must be in English)
- Ensure tables and figures are cited
- The preferred electronic format for text is Microsoft Word
- Manuscripts will be accepted in LaTeX as long as the native LaTeX and a PDF is also supplied
- Use International Systems of Units (SI) symbols and recognized abbreviations for units of measurement
- Do not punctuate abbreviations eg, et al, ie
- Spell out acronyms in the first instance in the abstract and paper
- Word counts are not specified. In general, shorter items range from 1000 to 3000 words and reviews from 3000 to 7,500
- Generic drug names are used in title, text, tables, and figures
- Suppliers of drugs, equipment, and other brand-name material are credited in parentheses (company, name, city, state, country)
- If molecular sequences are used, provide a statement that the data have been deposited in a publicly accessible database, eg, GenBank, and indicate the database accession number
- Depositing laboratory protocols on protocols.io is encouraged, where a DOI can be assigned to the protocol. To include a link to a protocol in your manuscript:
1) Describe your step-by-step protocol on protocols.io
2) Select "Get DOI" to issue your protocol with a unique DOI (digital object identifier)
3) Include the DOI link in the Methods section of your manuscript using the format provided by protocols.io: http://dx.doi.org/10.17504/protocols.io.xxxxxxx (where xxxxxxx is the unique DOI)
At this stage, your protocol is only visible to those with the link. This allows editors and reviewers to consult your protocol when evaluating the manuscript. You can make your protocols public at any time by selecting "Publish" on the protocols.io website. Any referenced protocols will automatically be made public when your article is published.
Updated 7 January 2019
Editorial Board
Dr Kaseb
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, United States
Editor-in-Chief: Dr. Ahmed Kaseb
Dr. Ahmed Kaseb is a Professor and Program Director of Hepatocellular Carcinoma (HCC), in the Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Dr. Kaseb received his medical degree from Cairo University, and worked as a research fellow at University of Michigan, in Ann Arbor for two years focusing on cancer biomarkers before starting Internal Medicine Residency at Wayne State University, in Detroit, Michigan where he excelled in clinical training and was the recipient of The Best Resident Award in 2003-2004. He then finished Medical oncology fellowship at Henry Ford Hospital, in Detroit, Michigan where he continued his translational research work which led to three major publications presenting circulating biomarkers for early cancer detection in the area of bladder and prostate cancers and his work on HCC biomarkers was subsequently initiated. Dr. Kaseb’s work received international awards from the American Society of Clinical Oncology (ASCO) an American College of Physicians (ACP).
Dr. Kaseb joined the department of Gastrointestinal Medical Oncology, at the University of Texas MD Anderson Cancer Center in 2007 to lead the HCC program. Dr. Kaseb is heavily involved in HCC clinical research where he has served as principal investigator on multiple clinical trials. Dr. Kaseb’s principal research interests include HCC systemic and multi-disciplinary therapies, in addition to molecular staging studies. His research also examines the differential effects of demographics and hepatitis status on treatment outcome in HCC. Based on his interest and research, he has developed several protocols in the treatment and staging of HCC. His published studies have yielded impressive results. Dr. Kaseb’s work has contributed greatly to the understanding of HCC interdisciplinary therapies and molecular staging, and has received governmental and pharmaceutical funding for several projects and clinical trials.
Dr. Kaseb has extensively authored and co-authored dozens of papers and books. Dr. Kaseb serves as an Editor and Scientific Reviewer for several international medical journals, and has received several national and international awards throughout his career. He is an active member of several international societies and has served on several committees and advisory boards at the national and international levels, and has participated in several international expert consensus conferences in the area of HCC.
Professor Furuse
Department of Internal Medicine, Medical Oncology, Kyorin University School of Medicine, Japan
ASSOCIATE EDITOR IN CHIEF
Associate Editor: Junji Furuse
Dr. Junji Furuse is a Professor in the Department of Medical Oncology, Kyorin University School of Medicine, Japan.
In 1984 Dr. Furuse graduated from Chiba University of Medical School and then joined the First Department of Internal Medicine, Chiba University. In 1992 he moved to the Department of Hepatobiliary and Pancreatic Medical Oncology at the National Cancer Center Hospital East, Chiba, Japan until 2008 when he began his current role.
Dr. Furuse is Chair of the Hepatobiliary and Pancreatic Oncology Group for the Japanese Clinical Oncology Group (JCOG). He is Director of the Japanese Society of Medical Oncology (JSMO) and the Director and Chair of the health insurance committee for the Japanese Pancreas Society (JPS). He is also on the council of the International Association of Pancreatology.
Dr. Furuse specializes in gastrointestinal medical oncology, especially hepatobiliary and pancreatic cancer.
Dr Murthy
Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, United States
ASSOCIATE EDITOR IN CHIEF
Associate Editor: Ravi Murthy
Ravi Murthy is a Professor of Interventional Radiology (IR), in the Division of Diagnostic Imaging, Department of Interventional Radiology at the University of Texas MD Anderson Cancer Center, Houston, Texas USA.
Dr. Murthy received his medical degree from St. John’s Medical College & Hospital in Bangalore University, Bangalore, India. He completed his Clinical Residencies in Internal Medicine at Robert Wood Johnson University Hospital in New Brunswick, NJ and Diagnostic Radiology at Morristown Memorial Hospital, Columbia Presbyterian College of Physicians & Surgeons, Morristown, NJ where he also served as Chief Resident. He completed his Clinical Fellowship in Vascular & Interventional Radiology, University Medical Center, Stony Brook, NY and American College of Radiology Information Network (ACRIN) Research Fellowship under the purview of Radiological Society of North America.
Dr. Murthy is ABIM certified in Internal Medicine, Diagnostic Radiology with CAQ in Vascular & Interventional Radiology. He has received various honors and awards such as Castle Connolly Top Doctor and Distinguished Reviewer Award for the Journal of Vascular and Interventional Radiology and is Fellow of the American College of Physicians.
Dr. Murthy has authored and co-authored numerous papers, books and articles and has received numerous national and international awards throughout his career. He is an active member of several societies and serves on several committees and advisory boards at the national and international levels
His research interests include Yttrium-90 microspheres for hepatic malignancies and image guided interventional trials.
Dr Wang
Laboratory of Human Carcinogenesis, National Cancer Institute, United States
ASSOCIATE EDITOR IN CHIEF
Associate Editor: Xin Wang
Dr. Wang is a Senior Investigator at the National Cancer Institute (NCI) where he oversees a basic/translational research program emphasizing new molecular approaches to define tumor subtypes and identify biomarkers for early detection, diagnosis, prognosis and prediction, to delineate the molecular mechanisms of liver cancer with applications towards precision medicine. Dr. Wang received his PhD training from New York University School of Medicine and further research training from Roche Institute of Molecular Biology and NCI. Currently, he also serves as Chief of the Liver Carcinogenesis Section and Deputy Chief of the Laboratory of Human Carcinogenesis, Center for Cancer Research at NCI. He is a world renowned liver cancer researcher with a special focus on cancer functional genomics. His lab utilizes state-of-the-art technologies to study liver cancer and other human malignancies. He leads several major international research initiatives on liver cancer genomics and clinical studies through collaborations with multiple universities and cancer centers. He is Honorary Professor of Fudan University and a recipient of several NIH Director’s Awards and NCI Director’s Awards for his outstanding scientific achievement in liver cancer research. He also is a recipient of the NCI Mentor’s Award for excellence in mentoring and guiding the careers of trainees in cancer research and Blue Faery Award for excellence in liver cancer research.
Editorial Board
Professor Beebe
UNITED STATES
Stephen J. Beebe, Professor, Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA, USA
Srikanta Dash, Professor, Director of Hepatitis Research Laboratory, Department of Pathology and Laboratory Medicine, Gastroenterology and Hepatology, Tulane University Health Sciences Center, New Orleans, LA, USA
Aldo Dettino, Professor in Clinical Oncology and Translational Research, Department of Clinical Oncology, A. C. Camargo Cancer Center, Sao Paulo-SP, Brazil.
Dan G. Duda, DMD, PhD, Director of Translational Research in GI Radiation Oncology, Investigator, Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Associate Professor of Tumor Biology, Harvard Medical School, Charlestown, MA, USA.
Dr Elghazaly
NOT SPECIFIED
Prof. Hesham Elghazaly , Professor of Clinical Oncology, Head of Medical Research Center MASRI, Ain Shams University, Cairo, Egypt.
Prof. Dr. Elsayes
UNITED STATES
Khaled Elsayes, Professor of Diagnostic Radiology, University of Texas MD Anderson Cancer Center and the Medical School of University Texas in Houston, USA
David Gerber, Professor and Division Chief, Division of Transplantation, Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Manal M Hassan, Associate Professor, Department of Epidemiology, Division of Cancer Prevention and Population Sciences, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Heping Hu, Director and Professor, Department of Heptobiliary Diseases, Eastern Hepatobiliary Hospital, Shanghai, People's Republic of China
Dr Kim
KOREA, REPUBLIC OF (SOUTH)
Do Young Kim, Associate Professor in Hepatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Philippe Merle, M.D., Ph.D., Professor of Hepato-Gastroenterology and Digestive Oncology, Leader of research team "Hepatocarcinogenesis and viral infections", UMR INSERM 1052 - CNRS 5286, Centre of Research in Cancerology, Lyon University and Croix-Rousse Hospital, Lyon, France
Dr Ganesh Nagarajan, Consultant Surgeon Hepatobiliary Pancreatic, GI oncology & Liver Transplant, P D Hinduja Hospital, Mumbai, India.
Ashraf Omar MD, Prof Hepatology &Liver Transplantation, Head Liver Cancer Clinic, Head of liver cancer society, Cairo University, Egypt.
Professor Patel
UNITED STATES
Tushar Patel, Professor of Medicine, Mayo Clinic College of Medicine, Jacksonville, FL, USA
Rodolfo Sacco, Director of Gastroenterology and Digestive Endoscopy Unit, Foggia University Hospital Medical School, Foggia, Italy.
Toshihito Seki, Professor and Director, Division of Gastroenterology and Hepatology, Kansai Medical University Medical Center, Osaka, Japan
Mohamed Kamal ElDin Aly Fahmy Shaker, President of the Egyptian Society for Liver Cancer; Member of the Supreme Committee of Hepatology Health Insurance Organisation; Emeritus Professor of Tropical Medicine and Hepatology Ain Shams University, Cairo, Egypt
Professor Shi
CHINA (PRC)
Ming Shi, Professor, Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, People's Republic of China
Prof. Dr. Stoeltzing
GERMANY
Oliver Stoeltzing, Head Doctor, Zentrum für Allgemein- und Viszeralchirurgie Riesa-Meißen, Elblandkliniken, Meißen, Germany.
Professor Tang
CHINA (PRC)
Hua Tang, Professor of Molecular Biology & Microbiology, School of Basic Medical Sciences, Tianjin Medical University, People's Republic of China
Harrys A. Torres, MD, FACP, FIDSA, Associate Professor of Medicine; Founding Director of Hepatitis C Clinic; Medical Director of Internal Medicine Center, Department of Infectious Diseases, Infection Control and Employee Health; Adjunct Associate Professor, Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Dr Tran Cao
UNITED STATES
Hop S. Tran Cao, MD, FACS, Assistant Professor of Surgery, Hepato-Pancreato-Biliary Section, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center.
Joerg Trojan, Professor of Medicine, Gastrointestinal Oncology, Goethe-University Medical Center, Frankfurt, Germany
Professor Wang
UNITED STATES
Jia-Sheng Wang, Professor and Head, Department of Environmental Health Science, College of Public Health, The University of Georgia, Athens, GA, USA
Chia-Jui Weng, Professor, Department of Living Services Industry, Tainan University of Tec
|
